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Abstract
Background: Calcitonin gene-related peptide (CGRP) has a key role in migraine pathophysiology and is associated
with activation of the trigeminovascular system. The trigeminal ganglion, storing CGRP and its receptor
components, projects peripheral to the intracranial vasculature and central to regions in the brainstem with Aδ-
and C-fibers; this constitutes an essential part of the pain pathways activated in migraine attacks. Therefore it is of
importance to identify the regions within the brainstem that processes nociceptive information from the
trigeminovascular system, such as the spinal trigeminal nucleus (STN) and the C1-level of the spinal cord.
Immunohistochemistry was used to study the distribution and relation between CGRP and its receptor
components - calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) - in human
and rat STN and at the C1-level, using a set of newly well characterized antibodies. In addition, double-stainings
with CGRP and myelin basic protein (MBP, myelin), synaptophysin (synaptic vesicles) or IB4 (C-fibers in general)
were performed.
Results: In the STN, the highest density of CGRP immunoreactive fibers were found in a network around fiber
bundles in the superficial laminae. CLR and RAMP1 expression were predominately found in fibers in the spinal
trigeminal tract region, with some fibers spanning into the superficial laminae. Co-localization between CGRP and
its receptor components was not noted. In C1, CGRP was expressed in fibers of laminae I and II. The CGRP staining
was similar in rat, except for CGRP positive neurons that were found close to the central canal. In C1, the receptor
components were detected in laminae I and II, however these fibers were distinct from fibers expressing CGRP as
verified by confocal microscopy.
Conclusions: This study demonstrates the detailed expression of CGRP and its receptor components within STN in
the brainstem and in the spinal cord at C1-level, and shows the possibility of CGRP acting postjunctionally in these
areas putatively involved in primary headaches.
Background
Migraine is considered as a neurovascular disorder
affecting more than 10% of the general population. Cal-
citonin gene-related peptide (CGRP) has a key role in
migraine, where levels of CGRP are increased during
acute migraine attacks [1]. CGRP is expressed through-
out the central and peripheral nervous systems, consis-
tent with control of vasodilatation and transmission of
nociceptive information. In migraine, CGRP is released
from the trigeminal vascular system. At peripheral
synapses, CGRP results in vasodilatation via receptors
on the smooth muscle cells. At central synapses, CGRP
has been suggested to act postjunctionally on second-
order neurons to transmit pain centrally via the brain-
stem and midbrain to higher cortical pain regions [2].
There are two forms of this peptide; (i) aCGRP, which
is predominantly expressed in the nervous system, and
(ii) bCGRP, which is primarily expressed in the enteric
sensory system. In the central nervous system (CNS),
CGRP is expressed in several regions such as the stria-
tum, amygdalae, hypothalamus, colliculi, brainstem, cer-
ebellum and the trigeminal complex [3-7]. Moreover,
CGRP is found in primary spinal afferent C- and Aδ-
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and its receptor components have not fully been studied
in man due to the fact that the receptor components
only fairly recently were characterized.
The receptor for CGRP consists of a complex of a
seven transmembrane-spanning protein, calcitonin
receptor-like receptor (CLR), a single transmembrane-
spanning protein designated receptor activity modifying
protein 1 (RAMP1) [8] and an intracellular protein,
receptor component protein (RCP) [9]. Recently, CGRP
antagonists have been developed with clinical efficacy
for the treatment of acute migraine attacks [10-12].
Consequently, it is of considerable importance to clarify
where the CGRP receptor is expressed which would
indicate possible sites for the therapeutic effect of these
antagonists. Hence, studies have focused on mapping
CGRP and its receptor components in the trigeminovas-
cular system and in the brainstem as recently reviewed
[13].
A migraine active region has been demonstrated in
the brainstem with positron emission tomography (PET)
[14-16]. It has been hypothesized that brainstem stimu-
lation can cause activation of the trigeminovascular sys-
tem, resulting in CGRP-dependent vasodilatation [17].
We have investigated in detail the distribution and
relationship of CGRP and its receptor components
within human and rat spinal trigeminal nucleus (STN)
in the brainstem and in the spinal cord at C1-level,
using a set of newly characterized antibodies for immu-
nohistochemistry [7]. Our main findings in the present
work were that CGRP and the receptor components
appear in different structures/regions of STN, and in
lamina I and II at C1-level, but do not co-localize. This
suggests that C-fiber released CGRP acts postjunction-
ally on fibers expressing CLR/RAMP1 in these regions.
Methods
Postmortem human tissue samples
Samples of STN and C1 were obtained at autopsy from
adult subjects in accordance with the Faculty of Medi-
cine University of Szeged guidelines for ethics in human
tissue experiments and were approved by the local Hun-
garian Ethics Committee. The tissue was bilaterally
removed from 6 subjects (3 female; 3 male) with an age
span of 65 to 86 years. None of the subjects suffered
from any central nervous system disease and the cause
of death was related to heart failure, septicemia or can-
cer. The tissues were collected within 24 to 36 hrs after
death.
The samples were immersed overnight in fixative con-
sisting of 4% paraformaldehyde (PFA) and in 0.1 mol/l
phosphate buffer, pH 7.2. After fixation, the specimens
were rinsed in sucrose-enriched (10%) Tyrode solution
overnight, frozen and stored at -80°C. The samples were
embedded in a gelatin medium (30% egg albumin and
3% gelatin in distilled water) and cryosectioned at 12
μm. The sections were stored at - 20°C until use.
Rat tissue samples
Brainstems were quickly removed from 5 male Sprague-
Dawley rats weighing 300-350 g (Scanbur, Stockholm,
Sweden). The STN samples were dissected at bregma
-14.08, corresponding the caudal part of STN, Sp5C
(using brain atlas Paxinos and Watson, second edition,
1986) and C1 were dissected at C1 vertebra. The tissues
were immediately placed in 4% PFA and fixed for 2-4
hrs. After fixation the tissues were rinsed in raising con-
centrations of sucrose in Sörensen’sp h o s p h a t eb u f f e r ,
embedded, sectioned and stored as the human samples.
Brainstems from 2 additional rats were after removal
kept in the refrigerator at +4°C for 24 hrs before they
were treated as above (to mimic the autopsy situation in
man).
Also, comparison was made to tissue obtained from 2
additional rats that were perfusion fixed with 4% PFA
(data not shown). We found no difference in the immu-
nostaining patterns between the two procedures. The
experiments were approved by the University Animal
Ethics Committee (M8-09), Lund University, Sweden.
Hematoxylin-Eosin staining
Human and rat sections were stained with Hematoxylin-
Eosin (Htx-Eosin) using a standard protocol (Htx 3 min,
water rinse, Eosin 1 min) for orientation and examina-
tion of the tissue condition. The areas within the rat
and human brainstem were identified by the use of a
brain atlas (Paxinos and Watson, second edition, 1986,
and Koutcherov et al. chapter 10 in The Human Ner-
vous System). Sections with STN (the caudal subdivi-
sion) or C1, were used and adjacent sections were
employed for immunohistochemistry.
Immunohistochemistry
Sections were thawed and washed for 10 min in PBS pH
7.2 containing 0.25% Triton X-100 (PBST). The sections
were blocked for 1 hr in blocking solution of PBS and
5% normal donkey or goat serum (depending on species
origin of the secondary antibody). After blocking, the
sections were incubated overnight at +4°C for single or
double immunolabelling with primary antibodies against
CGRP, CLR and RAMP1. Anti-human CLR (3152) and
RAMP1 (844) were used for the human material, anti-
rat CLR (3155, 132) and RAMP1 (3155) were used for
the rat material. For detailed description of the primary
antibodies, see Table 1.
The primary antibodies were diluted in PBST contain-
ing 1% BSA and 3% normal serum. After incubation
with primary antibodies, sections were equilibrated to
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exposed to secondary antibodies (for details, see Table
2) in PBST and 1% BSA for 1 hr at room temperature.
The sections were subsequently washed with PBST for 3
× 15 min. Vectashield, an anti-fading medium, contain-
ing DAPI (Vectashield, Vector Laboratories., Burlingame
CA) or glycerol in PBS were used as mounting media.
In addition, double immunostainings for CGRP
together with either myelin basic protein (MBP), synap-
tic vesicle protein (synaptophysin) or Isolectin IB4 (IB4)
were performed (Table 1). For all double immunostain-
ings, the antibodies were applied separately and not
mixed as a cocktail.
Controls and DAB staining
Omission of the primary antibody served as negative
controls for all antibodies.
To evaluate secondary antibody staining, three differ-
ent secondary antibodies (Table 2) were tested together
with CLR or RAMP1, respectively.
Preabsorption controls with blocking peptides (details
on these have been described before in [7]) were per-
formed with all CLR and RAMP1 primary antibodies.
Concentrations of the antibodies were the same as
described in Table 1, peptide concentrations were 100:1.
The blocking peptides were resuspended in PBS and
then incubated at +4°C overnight in PBST containing
1% BSA and 3% normal serum, with or without primary
antibodies. The immunostaining protocol was the same
as described above. Sections incubated with antibodies
alone versus blocked antibodies were compared.
In order to evaluate the fluorescence technique stain-
ing, 3,3’-diaminobenzidine (DAB) substrate together
with Vectastain ABC kit standard PK-6100 (Vector
Laboratories) was performed. In brief, sections were
rinsed in PBST followed by incubation with methanolic
hydrogen peroxidase (3% H2O2 and 10% MetOH in
PBS) to remove endogenous activity. After incubation
for 1 h with blocking solution of PBS and 5% normal
swine or rabbit serum, the sections were incubated with
primary antibodies against CGRP, CLR and RAMP1, at
+4°C overnight. At the second day, sections were incu-
bated with biotin-conjugated secondary antibodies, anti-
rabbit or anti-goat for 1,5 h (1:400, Dako, Glostrup,
Denmark). Visualization was achieved through the ABC
kit using DAB/H2O2. Omission of primary antibody
served as negative controls.
Microscopic analysis
Sections were examined and images were obtained using
a light- and epifluorescence microscope (Nikon 80i,
Tokyo, Japan) coupled to a Nikon DS-2MV camera.
Adobe Photoshop CS3 (v.8.0, Adobe Systems, Mountain
View, CA) was used to visualise co-labelling by superim-
posing the digital images and to adjust brightness and
contrast. In addition, confocal microscopy was
Table 1 Details on primary antibodies used for immunohistochemistry
Name and product code Host Dilution Detects Supplier
Calcitonin receptor-like receptor (CLR) 3152 Rabbit 1:500 C-terminal of human CLR Merck & Co., Inc, USA
CLR 3155 Rabbit 1:500 C-terminal of rat CLR Merck & Co., Inc, USA
CLR 132 Sheep 1:100 C-terminal of rat CLR Merck & Co., Inc, USA
Receptor activity-modifying protein 1 (RAMP1) 844 Goat 1:100 C-terminal of human RAMP1 Merck & Co., Inc, USA
RAMP1 3158 Rabbit 1:500 C-terminal of rat RAMP1 Merck & Co., Inc, USA
Calcitonin gene-related peptide (CGRP), polyclonal, B47-1 Rabbit 1:1600 rat CGRP Europroxima; Arnhem, The Netherlands
CGRP, monoclonal, ab81887 Mouse 1:100 rat a-CGRP Abcam; UK
Myelin basic protein (MBP) polyclonal, A0623 Rabbit 1:200 Myelin, Schwann cells Dako; Cophenhagen, Denmark
Synaptophysin, polyclonal, A0010 Rabbit 1:100 Synaptic vesicle protein Dako; Copenhagen, Denmark
Isolectin IB4 Alexa flour 594 conjugate, I21413 1:50 C-fibers (in general) Invitrogen; CA, USA
Table 2 Secondary antibodies used for immunohistochemistry
Conjugate and host Against Dilution Supplier
FITC (goat) anti-rabbit 1:100 Cayman Chemical, Ann Arbor, MI
Cy
2 (donkey) anti-rabbit 1:200 Jackson Immuoresearch, West Grove, PA
Texas-Red (donkey) anti-rabbit 1:200 Jackson Immuoresearch, West Grove, PA
Alexa 488 (donkey) anti-goat 1:400 Invitrogen, CA
Cy
2 (donkey) anti-goat 1:200 Jackson Immuoresearch, West Grove, PA
Cy
3(donkey) anti-goat 1:200 Jackson Immuoresearch, West Grove, PA
Texas-Red (donkey) anti-mouse 1:200 Jackson Immuoresearch, West Grove, PA
Texas-Red (donkey) anti-sheep 1:200 Jackson Immuoresearch, West Grove, PA
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Germany), where detailed localization and/or co-locali-
zation of immunoreactivity were recorded using the
confocal microscope. All pertinent questions were
addressed with examination with confocal microscope
analysis (see figures). The confocal microscopy was car-
ried out using 20× or 60× oil immersion lenses. Z
(frame) stacks were acquired using different laser chan-
nels one by one before next z position was acquired.
Laser channels used were 488 nm excitation (filter 515/
30) and 543 nm excitation (filter 605/75). Image ana-
lyses were conducted using NIS basic research software
(Nikon, Japan). Briefly, z stacks were 3-dimensionally
examined for detailed localization and distribution of
immunoreactivity, and for possible co-localization of the
antibodies used. The opportunity to move around 3-
dimensionally within the 12 μm thick section allows for
scrutinizing the detailed localization of the immunoreac-
tivity, but also for thorough evaluation of the immunor-
eactive structures.
Results
Histology
Htx-Eosin stained sections from human STN (A), C1 (B)
and rat STN (C) and C1 (D) are depicted in Figure 1.
The human samples were considered qualitatively
adequate for the immunofluorescence technique by and
large comparable in structures to that found in rat.
STN
CGRP immunoreactivity
In human STN, the highest density of CGRP immunor-
eactive fibers was found in a network around fiber bun-
dles in the superficial laminae (Figure 2A). In this area,
few fibers extended into the spinal trigeminal tract
region and into the mid part of the brainstem (Figure
2 A ) .T h eC G R Pi m m u n o r e a c t i v ef i b e r sw e r et h i na n d
displayed “pearl-like” structures (Figure 2A). No CGRP
positive cells were detected in the STN or in other
regions within the brainstem at the examined level.
Double-staining did not reveal any co-localization of
CGRP and MBP (myelin marker) (Figure 2B,C).
In rat STN, similar staining pattern of CGRP immu-
noreactivity was observed in the superficial laminae as
in man, with some fibers extending into the spinal tri-
geminal tract (Figure 3A). The expression of CGRP was
limited to fibers. However, in the region of the inferior
olive and the hypoglossal nucleus, CGRP positive neu-
rons were found. Here, CGRP immunoreactivity was
revealed as intracellular, granular staining in the cyto-
plasm, visualized with the two different CGRP antibo-
dies (Figure 3B). Double-staining did not reveal any co-
Figure 1 Hematoxylin-Eosin staining of human and rat STN (caudal subdivision, Sp5C) and C1-level of the spinal cord. (A) Human STN.
(B) Human C1. Arrow points at the posterior horn. (C) Rat STN, (arrow). (D) Rat C1. Arrow points at laminae I and II.
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and synaptic vesicle protein (synaptophysin) double-
staining showed co-expression of these two markers
(Figure 4C). CGRP and synaptophysin revealed same
results in human STN (data not shown).
CLR and RAMP1 immunoreactivity
In human STN, the staining of the receptor components
was not as distinct as the CGRP staining. Nevertheless,
CLR and RAMP1 positive fibers were found in the
spinal trigeminal tract region (Figure 5A). Double-
Figure 2 CGRP and MBP (myelin marker) expression in human STN. (A) Expression of CGRP in human STN. CGRP positive fibers are found in
network around fiber bundles in the superficial laminae. Few fibers extend into the spinal trigeminal tract region (arrow) and the mid part of the
brainstem (arrow heads). (B, C) Double-staining of CGRP (green) and MBP (red). Arrows point at MBP positive areas negative for CGRP. DAPI
(blue), staining nuclei, is used in the merged pictures.
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the spinal trigeminal tract region (Figure 5B). No CLR
or RAMP1 positive neurons were found. Double-stain-
ing did not reveal any co-localization of CGRP and
RAMP1 (Figure 5C) or CGRP and CLR (data not
shown).
Similar fiber staining pattern was seen in rat STN,
however, the staining was more intense. In contrast to
that of the human STN, positive CLR and RAMP1
staining was observed around fiber bundles within the
spinal trigeminal tract (Figure 6A). Double-staining of
CLR and RAMP1 showed co-localization in the spinal
trigeminal tract region, in both fiber bundles (Figure 6B)
and fibers spanning from the spinal trigeminal tract
(Figure 6C). Double-staining of CGRP and the receptor
components showed that CGRP is not expressed in the
same fibers as CLR (Figure 6D) or RAMP1 (data not
shown). No CLR or RAMP1 positive neurons were
found. Interestingly, the receptor components were
detected in the walls of capillaries within the rat brain-
stem (Figure 6).
C1
CGRP immunoreactivity
At the C1-level of the human spinal cord, CGRP posi-
tive fibers were detected within the posterior horn of
the gray matter, notably in laminae I and II (Figure 7A).
In addition, few fibers reaching the deeper laminae were
d e t e c t e d .N oC G R Pi m m u n o reactive neurons were
found in the human C1.
Double-staining revealed no co-localization of CGRP
and MBP, as the expression of the two markers was
observed in different structures at the C1-level (Figure
7B,C). CGRP was detected in areas that were absent
from MBP expression. Furthermore, CGRP and synapto-
physin were expressed in the same laminae and struc-
tures (Figure 8A), which was confirmed by confocal
microscopy (Figure 8B). Not all synaptophysin positive
fibers expressed CGRP. Expression of synaptophysin was
detected in all laminae within C1-level (Figure 8C).
The CGRP staining was similar in rat C1 compared to
man (Figure 9A). In rat, transverse positive CGRP fibers
were detected close to the central canal (Figure 9B). In
Figure 3 CGRP expression in rat STN. (A) CGRP staining of rat STN. Immunopositive fibers are mostly found in the superficial laminae (arrow)
and some fibers extending into the spinal trigeminal tract region (arrow head). Higher magnification shows the staining pattern in detail around
fiber bundles and displaying “pearl-like” immunoreactivity in the fibers. (B) CGRP positive neurons (visualized with two different primary
antibodies; green and red) in the region of the inferior olive and hypoglossal nucleus (arrows). The staining displays granular-like pattern in the
cytoplasm. CGRP positive fibers are also found close to the central canal (arrow heads).
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the central canal (Figure 9B). Double-staining with
CGRP and MBP (Figure 9C,D), CGRP and synaptophy-
sin (Figure 10A) revealed similar results as those seen in
the human samples. Synaptophysin expression was
detected in all laminae, including circular immunoreac-
tive fiber formations around neurons (Figure 10B). Dou-
ble-staining with CGRP and the IB4 marker revealed
CGRP and IB4 immunoreactivity in laminae I and II
(Figure 10C). IB4 staining was brighter in laminae II/III,
compared to laminae I and II. Confocal microscopy dis-
closed that CGRP and IB4 were most often not
expressed in the same fibers. However, occasionally the
slender CGRP positive fibers co-localized with the more
stubby IB4 immunoreactive fibers (Figure 10D, addi-
tional file 1, movie).
CLR and RAMP1 immunoreactivity
In human C1, the receptor components were detected
in laminae I and II, although the staining was weaker
compared to the CGRP staining (Figure 11A). No
Figure 4 Double-staining of CGRP and MBP or synaptophysin (synaptic vesicles). (A, B) Double-staining of CGRP (red) and MBP (green) in
rat STN. Nuclei staining (DAPI, blue) is used in the merged pictures. Arrows point at CGRP positive areas negative for MBP. (C) CGRP (red) and
synaptophysin (green) expression (arrows). Note that not all CGRP positive fibers co-localize with synaptophysin (arrow heads).
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staining of CGRP and RAMP1 showed no co-localiza-
tion (Figure 11B). Same results were observed with
CGRP and CLR (data not shown).
In rat C1, the staining for CLR and RAMP1 was more
prominent, although, the CLR staining was weaker
compared to that of RAMP1. The receptor components
were detected in fibers within laminae I and II (Figure
12A,B). Double-staining of CLR and RAMP1 showed co-
localization (Figure 12C). These fibers were different
from fibers containing CGRP, revealed by double-staining
of CGRP and the receptor components. Confocal
Figure 5 CLR/RAMP1 and CGRP double-staining in human STN. (A) Expression of RAMP1 in human STN. The expression is found in the
spinal trigeminal tract region (arrow). (B) Co-expression of the receptor components, CLR (green) and RAMP1 (red), in fibers in the spinal
trigeminal tract (arrows). (C) Confocal microscopy showing expression of CGRP (red, arrows) and RAMP1 (green, arrows). CGRP immunoreactivity
is found in the superficial laminae, while the receptor component is expressed in the spinal trigeminal tract. No co-localization is found. Asterisks
point at autofluorescent lipofuscin.
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ponents were not expressed in the same fibers (Figure
12D, additional file 2, movie). The receptor components,
especially RAMP1, were also detected close to the central
canal (laminae X) (Figure 12E). As for the STN of rat,
the receptor components were found in capillary walls
within the spinal cord at C1-level (Figure 12).
Controls and DAB staining
The negative controls (omission of primary antibody)
showed no immunoreactivity, except for the lipofuscin
autofluorescence in human samples (Figure 5, 7).
There was no immunoreactivity observed with preab-
sorbed CLR or RAMP1 antibodies, using their respective
blocking peptides (additional file 3).
Figure 6 CLR/RAMP1 and CGRP double-staining in rat STN. (A) Expression of CLR and RAMP1 in rat STN. The receptor components are
found around fiber bundles in the spinal trigeminal tract (arrows) and in the walls of capilliaries (arrow heads). (B, C) Double-staining of CLR
(red) and RAMP1 (green). They co-localize in fiber bundles and in fibers spanning from the spinal trigeminal tract (arrows). Arrow heads point at
co-expression in the capillaries. (D) CGRP and CLR double-staining, CGRP (red arrows) is mostly expressed in the superficial laminae while CLR
(green arrows) is expressed in the spinal trigeminal tract. No co-localization is found.
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for CGRP, CLR and RAMP1 as seen with the immuno-
fluorescence technique. DAB staining revealed CLR and
RAMP1 expression in the walls of capillaries in rat (Fig-
ure 12E) and in laminae X, close to the central canal.
Furthermore, three different secondary antibodies were
tested to ensure that the capillary staining was not due
to unspecific binding of the secondary antibody.
Two additional rat brainstems were kept at +4°C for
24 hrs before dissection, fixation and immunostaining to
mimic the autopsy situation in man. As in our previous
paper on the trigeminal ganglion [7]; this procedure did
Figure 7 CGRP and MBP expression in human C1. (A) Expression of CGRP in human C1. Positive fibers are found within the posterior horn,
mostly in laminae I and II. (B, C) Double-staining of CGRP (red) and MBP (green). Arrows point at CGRP positive areas negative for MBP. Nuclei
staining (DAPI, blue) is used in the merged pictures. Asterisks point at autofluorescent lipofuscin, which appears yellow in the merged pictures.
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RAMP1 as compared to fixation directly of fresh brain-
stems (data not shown).
Discussion
We have previously reported in detail the distribution of
CGRP and its receptor components in the human tri-
geminal ganglion [7]. Small to medium sized neurons of
the trigeminal ganglion store CGRP and have further
connections with STN in the brainstem, and in related
extensions down to the C1-2 level via un-myelinated C-
fibers [18]. CLR and RAMP1 are expressed in large neu-
rons and thick fibers, which are co-expressed with a
marker for Aδ-fibers. These fibers from the trigeminal
ganglion extend further to the brainstem. Several studies
point to the involvement of the brainstem in migraine
pathophysiology [1,19] and a region within the brain-
stem has been demonstrated to be active during attacks
in migraine patients [14,20].
The present study has revealed the detailed distribu-
tion and relations between CGRP and its receptor com-
ponents in human and rat projection regions from the
trigeminal ganglion. The study demonstrates for the first
time the expression of CLR and RAMP1 within human
STN in the brainstem and in the spinal cord at C1-level,
using a series of novel well characterized antibodies.
Thus, this indicates CGRP signaling in areas of the
brainstem/spinal cord putatively involved in the
migraine pathophysiology. The reason for choosing
these regions in the present study is based on a series of
detailed neuroanatomical mappings in rat showing pain
pathways that may be involved in primary headaches
[21].
Distribution of CGRP, CLR and RAMP1 in STN
We observed CGRP expression around nerve fiber bun-
dles in the superficial laminae of human and rat STN.
We found no CGRP expressing neurons in the STN
Figure 8 CGRP and synaptophysin expression in human C1. (A) Double-staining of CGRP (red) and synaptophysin (green) in human C1. Co-
localization is shown in the merged picture. (B) Detailed confocal image showing staining of CGRP (red, thin arrow) and synaptophysin (green,
thick arrow). Co-localization (yellow, arrow heads) is demonstrated in the fibers. (C) Synaptophysin and DAPI staining. “Pearl-like” synaptophysin
immunoreactivity (green) is detected in all laminae in the fibers within C1-level.
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small group of CGRP positive neurons located close to
the central canal, in the inferior olive and in the hypo-
glossal nucleus of the brainstem. Notably these neurons
were absent in man. The results were confirmed using 2
different antibodies against CGRP. The functional role
of CGRP in these regions remains to be disclosed. The
presence of CGRP in the brainstem is supported by
Figure 9 CGRP and MBP expression in rat C1. (A) CGRP expression in laminae I and II (arrow) in rat C1. (B) Transverse CGRP positive fibers
(arrows) and CGRP positive neurons (arrow heads) are found close to the central canal. (C, D) Double-staining of CGRP (red) and MBP (green).
Arrows point at CGRP positive areas negative for MBP. Nuclei staining (DAPI, blue) is used in the merged pictures.
Eftekhari and Edvinsson BMC Neuroscience 2011, 12:112
http://www.biomedcentral.com/1471-2202/12/112
Page 12 of 18Figure 10 Double-staining of CGRP and synaptophysin or IB4. (A) Double-staining of CGRP (red) and synaptophysin (green) in rat C1. (B)
Synaptophysin immunoreactivity is found all laminae, with fibers extending into to the white matter. Circular immunoreactive fiber formations
are seen around neurons (arrows). (C) Double-staining of CGRP (green, thin arrows) and IB4 (red, thick arrow). IB4 is mostly expressed in laminae
II/III. IB4 is also expressed in laminae I/II which could be seen as co-localization with CGRP. However, confocal microscopy (D) revealed that CGRP
(green, thin arrow) and IB4 (red, thick arrow) are most often not expressed in the same fibers. Occasionally the two markers co-localize in fibers
(arrow head).
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expression in STN and spinal cord of different species
has been studied [6,24-26]
The expression of CGRP in the brainstem differs
between species [6]. It has been shown that the distribu-
tion of CGRP fibers is similar in rat and alpaca brain-
stem. However, CGRP containing neurons are more
widespread in rat than in alpaca. In addition, the locali-
zation of CGRP positive neurons in the cat and alpaca
brainstem differs [27]. Hence, the distribution pattern
observed between rat and man in our study is likely due
to species differences.
CGRP and MBP double-staining showed no co-locali-
zation, indicating that CGRP is as expected expressed in
un-myelinated fibers in STN and this is in agreement
with a previous study on the trigeminal ganglion [7].
Synaptophysin, used as a marker for synaptic vesicles,
and CGRP were expressed in the same structures within
t h eS T N .T h i ss u p p o r t st h a tC G R Pi ss t o r e da n d
released from nerve terminals as supported by a study
on rat dorsal horn [28] and acts post-synaptic at CLR/
RAMP1 expressing fibers.
In human STN, we found CLR and RAMP1 positive
fibers mostly in the spinal trigeminal tract, spanning
towards the superficial laminae. In rat STN, expression
of CLR and RAMP1 were also found mostly in the
spinal trigeminal tract, around fiber bundles and fibers
in the spinal trigeminal tract spanning towards the
superficial laminae. These results are in contrast to an
earlier study by Lennerz et al., 2008, where CLR and
RAMP1 expression was detected in the superficial lami-
nae, partially co-localizing with CGRP. The reason for
this difference could reside in that different antibodies
were used.
There were no neuronal cell bodies immunopositive
for CLR and RAMP1 in the human or rat STN. CLR
and RAMP1 were observed to be co-expressed in the
fibers, suggesting the presence of functional CGRP
receptor in both types of species. Interestingly, we found
that the receptor components were co-expressed on the
walls of capillaries in rat STN
In rat STN, it was suggested that CGRP and its recep-
tor components are localized in terminals from primary
afferents [29]. In contrast, CLR did not co-localize with
neuropeptides of primary spinal afferents in the dorsal
horn of rat [30]. In the present work, we observed no
co-localization between the receptor components and
CGRP positive fibers, neither in man nor in rat. These
results suggest that CGRP and the receptor components
appear in nerve terminals, where C-fiber released CGRP
may act post-synaptic at CGRP receptors on second-
order neurons or modify the responses of trigeminal
Aδ-fibers.
Distribution of CGRP, CLR and RAMP1 in C1
We examined the localization and expression of CGRP
and its receptor components in the spinal cord at the
C1-level, since the main part of the trigeminovascular
projection occurs at this level [21]. CGRP positive fibers
were found in laminae I and II. Similar staining pattern
has been demonstrated previously in the chick, quail
dorsal horn of the spinal cord [31] and in the cat [32].
In addition, we observed some CGRP positive neurons
and fibers close to the central canal (laminae X). This
f i n d i n gi si na g r e e m e n tw i t hap r e v i o u ss t u d yi nr a t
spinal cord with neurons being positive for CGRP [6].
To determine which fibers express CGRP, co-localiza-
tion experiments were performed with CGRP and IB4.
IB4 has previously been used as a marker for C-fibers
[30]. In the present study we found that IB4 and CGRP
could be expressed in the same laminae, but most often
in different types of fibers. This observation was con-
firmed by confocal microscopy. The IB4 staining was
more prominent in the deeper laminae of the spinal
cord, which is in agreement with a study of rat spinal
cord [30]. It has been shown that the degree of co-
expression of CGRP and IB4 in neurons vary in the rat.
More neurons expressing both markers are found in
dorsal root ganglia compared to the trigeminal ganglion
of rat [33]. Electron microscopy showed that IB4 and
CGRP expressing axons were distinct, but both could be
present in the same bundle of un-myelinated fibers [34].
The MBP marker showed that in some areas within
laminae I and II myelinated fibers are absent. Co-stain-
ing experiments with CGRP showed that CGRP is
Figure 11 CLR/RAMP1 and CGRP double-staining in human C1.
(A) Expression of RAMP1 and CLR in human C1. The receptor
components are found within laminae I and II. (B) Double-staining
of CGRP (red) and RAMP1 (green) shows that CGRP positive fibers
(arrows) within laminae I and II do not co-localize with RAMP1.
Asterisks point at autofluorescent lipofuscin.
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Page 14 of 18Figure 12 CLR/RAMP1 and CGRP double-staining in rat C1. (A) RAMP1 and (B) CLR expression in rat C1. The receptor components are found
from Lissauer’s tract and within laminae I and II (arrows). Higher magnification discloses expression in the walls of the capillaries. (C) Co-
expression of CLR (red) and RAMP1 (green) in the laminae and the capillaries. (D) Double-staining of CGRP (red, thick arrows) and RAMP1 (green,
thin arrows) using confocal microscopy. CGRP and RAMP1 are not co-expressed. (E) Fluorescence and DAB staining of the receptor components.
Positive fibers are displayed close to the central canal (arrows), where also positive capillaries are found (arrow heads).
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Page 15 of 18expressed in areas that are absent of MBP, suggesting
that CGRP is indeed expressed in un-myelinated fibers.
To further scrutinize the CGRP positive fibers, dou-
ble-staining of CGRP and synaptophysin was performed.
In laminae I and II, where CGRP staining was found,
co-expression of CGRP and synaptophysin was
observed. With confocal microscopy, we obtained a
detailed three-dimensional view of the staining pattern.
This clearly showed that CGRP and synaptophysin were
detected in the same fibers.
Reportedly, CLR and RAMP1 are expressed in fibers
within laminae I and II in the dorsal horn of rat spinal
cord [30]. Similar observation but in different tissue was
seen in our study; CLR and RAMP1 expressions were
found within laminae I and II of human and rat C1. No
CLR or RAMP1 positive neuronal cell bodies were
observed at the C1-level. In rat, CGRP was expressed in
the same laminae, but it did not co-localize with CLR or
RAMP1. CLR and RAMP1 were co-expressed, suggest-
ing expression of functional CGRP receptor in fibers
within laminae I and II. The presence of receptor com-
ponents in the spinal cord is supported by the mRNA
expression of RAMP1 and RCP, detected with specific
oligonucleotides for in situ hybridization [35].
CLR and RAMP1 were in addition detected in fibers
close to the central canal. As described above, CGRP
positive fibers were also detected in this area. Interest-
ingly, tracing experiments in cat have revealed projec-
tions from the periaqueductal gray (PAG) region to the
spinal cord. Horseradish peroxidase (HRP) injections
into the PAG region resulted in labeled fibers close to
the central canal, terminating in laminae X of C1 and
C2-levels [36]. The same authors found labeled fibers in
segments C4 to T8 adjoining the ependymal layer of the
central canal and next to the basal membrane of the
nearby capillaries. Histochemical studies in different
species have revealed neurons, axons and terminals
within laminae X containing neuropeptides such as sub-
stance P [37]. Thus, our results demonstrate fibers con-
taining CGRP and its receptor components close to the
central canal. The function of this is not known; one
may speculate that these fibers can release CGRP
directly into the cerebrospinal fluid or stimulate the
ependymal cells of the central canal.
Methodology and technical considerations
The hematoxylin-eosin stained material revealed well-
preserved human tissue adequate for immunofluores-
cence technique, even though the tissue samples were
collected 24 to 36 hrs after death. Due to the relatively
high age of the subjects, lipofuscin is accumulated in the
tissue, causing auto-fluorescence. We have earlier exam-
ined, in rat trigeminal ganglion, if storage of the animals
for 24 hrs at +4°C prior fixation would affect the
immunohistochemistry; which was not the case [7].
Similar results were obtained in the present study on
the rat brainstem (data not shown). In rat we also per-
formed a direct comparison of perfusion-fixed and
immersion-fixed brainstems, and found no observable
difference in antibody expression pattern.
T h eC 1 - l e v e lc o m p a r e dw e l li nt h eP a x i n o sa t l a sf o r
rat and man. The STN is a structure that is distributed
for a considerable length in the brainstem and could
therefore not be examined for its entire distribution. It
is a limitation of the present study that we only studied
a portion of the STN; the exact part is given in the
method part.
In our previous study, antibodies against human and
rat CLR and RAMP1 were generated, and the specificity
of the antibodies was confirmed in HEK293 cells stably
expressing the human CGRP receptor. The specificity of
the raised antibodies was also confirmed by Western
blotting [7]. The same antibodies were used in this
study.
The staining of the receptor components was weaker
and a bit more diffuse in the human tissue compared to
rat. This could be due of several factors: differences in
antibodies recognizing the epitopes, tissue condition, or
low level of CLR and RAMP1 in human tissue. In rat
STN and C1, the RAMP1 antibody displayed a stronger
staining pattern compared to the CLR antibody. If this
was due to differences in antibody recognizing the epi-
topes or more expression of RAMP1 in these areas
could not be verified.
Within the rat brainstem, we found expression of
RAMP1 and CLR in the capillary walls. This was
blocked with the specific blocking peptides (epitopes
used in the production of the respective antibodies).
The staining of the capillaries was similar in the endo-
genously activity blocked DAB-stained sections.
Conclusions
The neuropeptide CGRP is implicated in the pathophy-
s i o l o g yo fm i g r a i n ea n dt h eC G R Pr e c e p t o rh a sl o n g
been regarded as a useful target for the development of
novel antimigraine therapies. We have described in
detail CGRP and its receptor components in the STN
and C1 of man and rat using immunohistochemistry.
Fibers expressing CGRP and its receptor components
occur in STN and C1, however they were not co-
expressed in the different areas and laminae. This sug-
gests that CGRP released from C-fibers in the brainstem
may act postjunctionally to modulate the activity in
fibers that store the CGRP receptor in these regions.
Differences in the CGRP expression between the species
were observed in other parts of the brainstem. We have
also demonstrated fibers and neurons expressing CGRP
close to the central canal which suggests that CGRP
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Page 16 of 18may have a function within this area. Further efforts are
essential to understand CGRP signaling and its function
within the brainstem.
Additional material
Additional file 1: Movie: 3-dimensionally view of staining with CGRP
(green) and IB4 (red) in rat C1. The two markers are most often not
expressed in the same fibers. Occasionally the two markers co-localize in
fibers (yellow).
Additional file 2: Movie: 3-dimensionally view of staining with CGRP
(red) and RAMP1 (green) in rat C1. The neuropeptide CGRP and the
receptor component RAMP1 are found within the same laminae, but
they are not co-expressed in the same structures.
Additional file 3: Blocking peptide experiments. CLR and RAMP1
antibodies were pre-absorbed with their respective blocking peptides. No
positive immunoreactivity is found when the blocking peptides are used.
Asterisks point at autofluorescent lipofuscin in the human samples.
Human STN (A) preabsorption for CLR, (B) preabsorption for RAMP1. Rat
STN (C) preabsorption for CLR, (D) preabsorption for RAMP1. Human C1
(E) preabsorption for CLR, (F) preabsorption for RAMP1. Rat C1 (G)
preabsorption for CLR, (H) preabsorption for RAMP1.
Abbreviations
BSA: Bovine serum albumin; CLR: Calcitonin receptor-like receptor; CGRP:
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